Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

Shaw Alice T.; Gandhi Leena; Gadgeel Shirish; Riely Gregory J.; Cetnar Jeremy; West Howard; Camidge D. Ross; Socinski Mark A.; Chiappori Alberto; Mekhail Tarek; Chao Bo H.; Borghaei Hossein; Gold Kathryn A.; Zeaiter Ali; Bordogna Walter; Balas Bogdana; Puig Oscar; Henschel Volkmar; Ou Sai-Hong Ignatius

首页> 外文期刊>The lancet oncology >Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

【24h】

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

机译：Alectinib治疗ALK阳性，耐克唑替尼的非小细胞肺癌：单组，多中心，2期试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background Alectinib-a highly selective, CNS-active, ALK inhibitor-showed promising clinical activity in crizotinibnaive and crizotinib-resistant patients with ALK-rearranged (ALK-positive) non-small-cell lung cancer (NSCLC). We aimed to assess the safety and effi cacy of alectinib in patients with ALK-positive NSCLC who progressed on previous crizotinib.

机译：背景Alectinib是一种高度选择性的，具有CNS活性的ALK抑制剂，在患有crizotinibnaive和crizotinib耐药的ALK重排（ALK阳性）非小细胞肺癌（NSCLC）的患者中显示出有希望的临床活性。我们的目的是评估艾乐替尼在先前使用克唑替尼治疗的ALK阳性非小细胞肺癌患者中的安全性和有效性。

著录项

来源
《The lancet oncology》 |2016年第2期|共9页
作者
Shaw Alice T.; Gandhi Leena; Gadgeel Shirish; Riely Gregory J.; Cetnar Jeremy; West Howard; Camidge D. Ross; Socinski Mark A.; Chiappori Alberto; Mekhail Tarek; Chao Bo H.; Borghaei Hossein; Gold Kathryn A.; Zeaiter Ali; Bordogna Walter; Balas Bogdana; Puig Oscar; Henschel Volkmar; Ou Sai-Hong Ignatius;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. on behalf of the study investigators. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial (vol 17, pg 234, 2016) [J] . Shaw A. T., Gandhi L., Gadgeel S. The lancet oncology . 2017,第3期

机译：代表学习调查人员。 alectidib在Alk阳性，抵抗，非小细胞肺癌中：单一组，多期，第2阶段试验（Vol 17，PG 234,2016）
2. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial [J] . Shaw Alice T., Gandhi Leena, Gadgeel Shirish, The lancet oncology . 2016,第2期

机译：Alectinib治疗ALK阳性，耐克唑替尼的非小细胞肺癌：单组，多中心，2期试验
3. Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial [J] . Yang Yunpeng, Zhou Jianya, Zhou Jianying, The lancet. Respiratory medicine. . 2020,第1期

机译：菌根抗性，ALK阳性非小细胞肺癌中的疗效，安全性和生物标志物分析：多期，第2期试验
4. Matrix Regenerative Nanoparticles to Improve the Tumor Microenvironment in Non-Small-Cell Lung Cancers [C] . Dhruv R. Seshadri, Anand Ramamurthi Society for Biomaterials annual meeting and exposition . 2018

机译：基质再生纳米颗粒改善非小细胞肺癌的肿瘤微环境
5. Pharmacology Profiles of ALK and FLT3 Kinase Inhibitors against Non-Small-Cell Lung Cancer Cells and Acute Myeloid Leukemia Cells with Cancer Driver Mutations [D] . 森政道 2019

机译：ALK和FLT3激酶抑制剂对非小细胞肺癌细胞和急性髓系白血病细胞的癌症驱动突变的药理作用
6. Phase 2 prospective analysis of alectinib in ALK-positive crizotinib-resistant non-small-cell lung cancer [O] . Alice T. Shaw, Leena Gandhi, Shirish Gadgeel, -1

机译：艾乐替尼治疗ALK阳性耐克唑替尼的非小细胞肺癌的2期前瞻性分析
7. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib [O] . Edward S Kim, Fabrice Barlesi, Tony Mok, 2021

机译：Alta-2：在Alectinib或Ceritinib上进行的ALK阳性，晚期非小细胞肺癌患者中的Brigatinib的II期研究

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

摘要

著录项

相似文献

相关主题

期刊订阅